Monoclonal antibody 3S193 - Recepta biopharma

Drug Profile

Monoclonal antibody 3S193 - Recepta biopharma

Alternative Names: 3S193; Anti-Lewis Y monoclonal antibody 3S193; hu3S193; Hu3S193 - RECEPTA biopharma; mAb Hu3S193 - Anti-LeY; RebmAb 100

Latest Information Update: 12 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ludwig Institute for Cancer Research
  • Developer Recepta biopharma; University of Sao Paulo
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Lewis Y antigen antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 05 Dec 2017 Efficacy and adverse events data from a phase II trial in Breast cancer presented at the 40th Annual San Antonio Breast Cancer Symposium (SABCS-2017)
  • 06 Jun 2017 Efficacy and adverse events data from a phase II trial in Ovarian cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 16 Nov 2015 Recepta Biopharma terminates a phase II trial in Ovarian cancer (Second-line therapy or greater, Platinum resistant/refractory) in Brazil since the total number of patients expected to be enrolled was not met (NCT01137071)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top